Quantcast
Last updated on April 23, 2014 at 11:01 EDT

Latest Acetonide Stories

2014-04-14 12:33:11

PDUFA goal date set for September 26, 2014 ATLANTA, April 14, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its recent resubmission of the New Drug Application (NDA) for ILUVIEN(®) has been acknowledged as received by the U.S. Food and Drug Administration (FDA) as a complete class 2 response to the...

2013-08-12 08:30:32

ALLEGAN, Mich., Aug. 12, 2013 /PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug applications for fluocinolone acetonide scalp oil, 0.01%, the generic equivalent to Derma-Smoothe/FS® Scalp Oil, and fluocinolone acetonide topical oil, 0.01%, the generic equivalent to Derma-Smoothe/FS® Body Oil. Perrigo expects to begin shipments of both products next month....

2013-07-31 23:18:37

David P. Skoner, MD, of Allegheny General Hospital was chosen to represent the opinions of major national allergy medicine societies in opposing the over-the-counter sale of triamcinolone acetonide (Nasacort) to kids and adults. Silver Spring, Md. (PRWEB) July 31, 2013 David P. Skoner, MD, Director of the Division of Allergy, Asthma and Immunology, Department of Medicine at Allegheny General Hospital (AGH), will testify today before the U.S. Food and Drug Administration in opposition to...

2013-05-03 12:25:30

ATLANTA, May 3, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its first quarter fiscal year 2013 financial results after the market close on Thursday, May 9, 2013. An investor conference call will follow on the same day at 4:30 p.m. ET. The conference call will be hosted by Dan Myers,...

2013-03-11 16:25:09

ATLANTA, March 11, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2012 financial results after the market close on Thursday, March 21, 2013. An investor conference call will follow on the same day at 4:30 p.m. ET. The conference call will be hosted by Dan...

2013-02-20 08:28:11

ATLANTA, Feb. 20, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will participate in the Credit Suisse London One-on-One Healthcare Conference on March 5 - 6, 2013 in London, UK. About Alimera Sciences, Inc. Alimera Sciences, Inc., based in...

2013-01-23 08:28:15

ATLANTA, Jan. 23, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has published final guidance indicating that ILUVIEN(®) is not cost effective for the treatment of chronic diabetic macular edema (DME) considered insufficiently...

2012-12-04 16:26:59

ATLANTA, Dec. 4, 2012 /PRNewswire/ -- Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced it has signed a Master Services Agreement with Quintiles Commercial Europe Ltd. (Quintiles) for the commercial launch of ILUVIEN(® )in certain European countries. ILUVIEN is Alimera's product for the treatment of chronic diabetic macular edema...

2012-12-03 12:27:00

ATLANTA, Dec. 3, 2012 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Oppenheimer 23(rd) Annual Healthcare Conference at 4:30 P.M. ET on Wednesday, December 12, 2012 at The Waldorf Astoria Hotel in New York City. The presentation will be...

2012-11-29 20:22:13

ATLANTA, Nov. 29, 2012 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance indicating that ILUVIEN is not recommended for the treatment of chronic diabetic macular edema (DME) considered insufficiently...